Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
- 31 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 38 (1), 167-177
- https://doi.org/10.1093/schbul/sbq042
Abstract
While all second-generation antipsychotics (SGAs) are promoted for having a low risk of extrapyramidal side effects (EPS), clinical observations suggest differences between the various agents. Nevertheless, this question has never been examined in a systematic review and meta-analysis of head-to-head comparisons. We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE (last search July 2009) for randomized, blinded studies comparing the following SGAs in the treatment of schizophrenia or related disorders: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, and zotepine. At least 3 reviewers extracted the data independently. The primary outcome was "use of antiparkinson medication." The results were combined in a meta-analysis. We included 54 studies with 116 arms. Risperidone was associated with more use of antiparkinson medication than clozapine, olanzapine, quetiapine, and ziprasidone. Ziprasidone showed more use of antiparkinson medication than olanzapine and quetiapine and zotepine more than clozapine. There was no significant difference between amisulpride and its comparators (olanzapine, risperidone, or ziprasidone). Quetiapine showed significantly less use of antiparkinson medication than the 3 other SGAs it was compared with (olanzapine, risperidone, and ziprasidone). Scale-derived data (Barnes Akathisia Scale and Simpson Angus Scale) were limited. Our meta-analysis demonstrates that there are differences between the SGAs in their ability to induce EPS that clinicians consider warrant treatment with antimuscarinic drugs. Even though the differences were relatively small, they might be important for individual patients and should be taken into account in drug choice.Keywords
This publication has 45 references indexed in Scilit:
- The Expert Consensus Guideline SeriesThe Journal of Clinical Psychiatry, 2009
- Akathisia: An Updated Review Focusing on Second-Generation AntipsychoticsThe Journal of Clinical Psychiatry, 2009
- Second-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychological Medicine, 2009
- A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of SchizophreniaAmerican Journal of Psychiatry, 2009
- Extrapyramidal side-effects of antipsychotics in a randomised trialThe British Journal of Psychiatry, 2008
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialThe Lancet, 2008
- How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trialsMolecular Psychiatry, 2008
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseNew England Journal of Medicine, 2006
- Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical FindingsSchizophrenia Bulletin, 1997
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986